Clinical trial
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for…
NCT00318890 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00318890 |
|---|---|
| Title | Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck |
| Official title | A Phase I/II Trial of Induction Cisplatin and Docetaxel Followed by Concomitant Docetaxel/Radiotherapy With Subcutaneous Amifostine for Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of Head and Neck, Head Cancer, Head and Neck Cancer, Neck Cancer, Neck Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | Cisplatin, Docetaxel, Radiotherapy, Amifostine |
| Enrollment | 48 |
| Start date | Oct 1, 2002 |
| Primary completion | Apr 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 27, 2006 |
| Last update posted | Feb 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: